Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2022  |  Volume : 18  |  Issue : 2  |  Page : 567-575

Significance of vasohibin 1 in cancer patients: A systematic review and meta analysis


1 Department of Breast Disease Diagnosis and Treatment Center, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University; Department of Breast Disease Diagnosis and Treatment Center, Central Hospital Affiliated to Shandong First Medical University, Jinan Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
2 Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, Shandong, China
3 Department of Breast Disease Diagnosis and Treatment Center, Central Hospital Affiliated to Shandong First Medical University, Jinan Central Hospital Affiliated to Shandong First Medical University; Department of Oncology, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
4 Department of Radiation Oncology; Department of Thoracic Surgery National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
5 Clinical Study Center, Shandong Cancer Hospital and Institute, Jinan, Shandong, China
6 Department of Breast Disease Diagnosis and Treatment Center, Central Hospital Affiliated to Shandong First Medical University, Jinan Central Hospital Affiliated to Shandong First Medical University; Medical Research and Laboratory Diagnostic Center, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China

Correspondence Address:
Yunshan Wang
Medical Research and Laboratory Diagnostic Center, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250013, Shandong; Jinan Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, Shandong
China
Yuping Sun
Phase I Clinical Study Center, Shandong Cancer Hospital and Institute, Jinan 250117, Shandong
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jcrt.jcrt_281_21

Rights and Permissions

This study analyzed the role of vasohibin-1 (VASH1) in human cancer outcomes. Relevant original studies on VASH1 expression in cancers were searched from PubMed, ClinicalKey, and Cochrane Library databases. A meta-analysis was performed to evaluate the role of VASH1 in clinicopathological characteristics and overall survival (OS) of patients with tumors. Statistical analysis was performed using the RevMan v. 5.3 software. Our meta-analysis results showed that patients with high VASH1 expression experienced a significantly poor prognosis with a hazard ratio (HR) of 1.69 (95% confidence interval [CI], 1.16– 2.46, P = 0.006) for OS, and an HR of 2.21 (95% CI, 1.32–3.68, P = 0.003) for progression-free survival. Furthermore, the high expression of VASH1 was significantly relevant to advanced tumor node metastasis stages. Thus, VASH1 is a potential biomarker to predict unfavorable clinical outcomes, serving as a potential tumor treatment target.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed568    
    Printed10    
    Emailed0    
    PDF Downloaded23    
    Comments [Add]    

Recommend this journal